文献速递神经免疫

阿仑单抗治疗后出现白癜风:继发性自身免疫并非仅与B细胞有关

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
PubMed 文献 · Neurology · 2018-11-07

回顾性病例系列报告3例复发缓解型多发性硬化(RRMS)患者在阿仑单抗治疗后52、18、14个月出现白癜风,皮损示黑素细胞缺失伴CD8+ T细胞浸润;其中1例外周血CD8+ T细胞呈活化、记忆及1型细胞因子表型,TCR克隆性增高、多样性降低。

要点

  • 阿仑单抗治疗RRMS后可在52、18、14个月出现白癜风。
  • 皮损示黑素细胞缺失及CD8+ T细胞浸润的界面皮炎。
  • 1例患者CD8+ T细胞克隆性增高、TCR多样性降低。

核心结论

  • 3例白癜风是阿仑单抗治疗后T细胞介导的继发性自身免疫病的详细描述。
  • 当前B细胞反应释放的概念可能未覆盖阿仑单抗相关继发性自身免疫的全部方面。
  • 机制研究尤其是TCR repertoire研究可能有助于阐明潜在机制。

研究设计与样本

  • 回顾性病例系列,包括外周血单核细胞的流式细胞分析及T细胞受体(TCR)测序。

主要发现

  • 3例RRMS患者在阿仑单抗开始后52、18、14个月出现白癜风。
  • 组织病理示表皮色素丢失、黑素细胞缺失及CD8+ T细胞浸润的界面皮炎。
  • 1例患者白癜风发作时CD8+ T细胞高比例表达活化(HLA-DR+)、记忆(CD45RO+)及1型细胞因子(干扰素-γ+肿瘤坏死因子-α)表型,对照为30例阿仑单抗治疗的RRMS患者。
  • 该患者CD8 TCR repertoire克隆性高度增高、多样性降低,对照为健康对照及未治疗RRMS患者。
  • 该患者基线时以单一克隆为主,阿仑单抗治疗未实质性影响多数优势克隆的比例随时间的变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report 3 patients with relapsing-remitting multiple sclerosis (RRMS) showing vitiligo after treatment with alemtuzumab. METHODS: Retrospective case series including flow cytometric analyses and T-cell receptor (TCR) sequencing of peripheral blood mononuclear cells. RESULTS: We describe 3 cases of alemtuzumab-treated patients with RRMS developing vitiligo 52, 18, and 14 months after alemtuzumab initiation. Histopathology shows loss of epidermal pigmentation with absence of melanocytes and interface dermatitis with CD8+ T-cell infiltration. Also compatible with pathophysiologic concepts of vitiligo, peripheral blood mononuclear cells of one patient showed high proportions of CD8+ T cells with an activated (human leukocyte antigen-DR+), memory (CD45RO+), and type 1 cytokine (interferon-γ + tumor necrosis factor-α) phenotype at vitiligo onset compared to a control cohort of alemtuzumab-treated patients with RRMS (n = 30). Of note, analysis of CD8 TCR repertoire in this patient revealed a highly increased clonality and reduced repertoire diversity compared to healthy controls and treatment-naive patients with RRMS. We observed a predominance of single clones at baseline in this patient and alemtuzumab treatment did not substantially affect the proportions of most abundant clones over time. CONCLUSION: The 3 cases represent a detailed description of vitiligo as a T-cell-mediated secondary autoimmune disease following alemtuzumab treatment. The prevailing concept of unleashed B-cell responses might therefore not cover all facets of alemtuzumab-related secondary autoimmunity. Mechanistic studies, especially on TCR repertoire, might help clarify the underlying mechanisms.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, et al. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. Neurology. 2018. PMID: 30404783. doi:10.1212/WNL.0000000000006648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。